---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-037852"
form_type: "8-K"
ticker: null
cik: "0001100397"
company_name: "Ayala Pharmaceuticals, Inc."
filed_at: "2023-10-20T23:59:59+00:00"
generated_at: "2026-06-09T18:02:43.645972+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Ayala Pharmaceuticals closes merger with Biosight, adds AML drug aspacytarabine

## Summary
- Merger completed Oct 18, 2023; ~5.9M Ayala shares issued to former Biosight holders at 1.82285 exchange ratio.
- Pipeline expands: adds aspacytarabine (BST-236) for AML; Phase 3 AL102 for desmoid tumors continues.
- Roy Golan appointed CFO, replacing interim CFO Igor Gitelman, effective at closing.
- Board changes: Dr. Samir Khleif resigned; new directors Yuval Cabilly, Pini Orbach, Bridget Martell appointed.
- Combined company continues on OTCQX under ticker ADXS.

## SEC filing metadata
- accession: 0001493152-23-037852
- form_type: 8-K
- cik: 0001100397
- company_name: Ayala Pharmaceuticals, Inc.
- filed_at: 2023-10-20T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.01, 3.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1100397/000149315223037852/0001493152-23-037852-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1100397/000149315223037852/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-037852
- JSON: https://secwatch.observer/filing/0001493152-23-037852.json
- Plain text: https://secwatch.observer/filing/0001493152-23-037852.txt

## Key facts
- Executive change
  Bridget Martell was appointed as Director at Ayala Pharmaceuticals, Inc..
  - Action: appointed
  - Role: Director
  source text: Bridget Martell, M.D.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1100397/000149315223037852/0001493152-23-037852-index.htm
- Executive change
  Samir Khleif resigned as Director at Ayala Pharmaceuticals, Inc..
  - Action: resigned
  - Role: Director
  source text: immediately prior to the Effective Time, Dr. Samir Khleif resigned from the Board of the Registrant.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1100397/000149315223037852/0001493152-23-037852-index.htm
- Executive change
  Roy Golan was appointed as Chief Financial Officer at Ayala Pharmaceuticals, Inc..
  - Action: appointed
  - Role: Chief Financial Officer
  source text: Effective as of the Effective Time, Roy Golan, CPA, LLM, will become the Registrant’s Chief Financial Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1100397/000149315223037852/0001493152-23-037852-index.htm
- Executive change
  Yuval Cabilly was appointed as Director at Ayala Pharmaceuticals, Inc..
  - Action: appointed
  - Role: Director
  source text: Yuval Cabilly, Ph.D .
  evidence_url: https://www.sec.gov/Archives/edgar/data/1100397/000149315223037852/0001493152-23-037852-index.htm
- Executive change
  Igor Gitelman departed as Interim Chief Financial Officer at Ayala Pharmaceuticals, Inc..
  - Action: ceased to serve
  - Role: Interim Chief Financial Officer
  source text: Igor Gitelman will cease to serve as the Company’s Interim Chief Financial Officer at that time.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1100397/000149315223037852/0001493152-23-037852-index.htm
- Executive change
  Pini Orbach was appointed as Director at Ayala Pharmaceuticals, Inc..
  - Action: appointed
  - Role: Director
  source text: Pini Orbach, Ph.D .
  evidence_url: https://www.sec.gov/Archives/edgar/data/1100397/000149315223037852/0001493152-23-037852-index.htm
- M&A Transactions
  Ayala Pharmaceuticals, Inc. completed an acquisition involving Biosight Ltd. (closed 2023-10-18).
  - Action: acquisition
  - Counterparty: Biosight Ltd.
  - Closing: 2023-10-18
  source text: On October 18, 2023 (the “Closing Date”), pursuant to the Merger Agreement, Merger Sub consummated the merger with and into Biosight, with Biosight continuing as the surviving company and a wholly-owned subsidiary of the Registrant (the “Merger”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1100397/000149315223037852/0001493152-23-037852-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.